N/A N=4,107 Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine
Crohn's Disease
Primary: Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) at Each Visit — -117; -124; -131; -137 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=418 Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: 2-Year Progression Free Survival (PFS) Rate — 0.64; 0.71; 0.74 proportion of participants
Phase 4 N=20 Treatment of Nicotine Dependence and Acute Depression
Major Depressive Disorder · Nicotine Dependence
Primary: Hamilton Depression Scale Score — -.5322 percentage of change in depression — p=<.001
N/A N=261 Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers
Intensive Care Unit Survivors · Informal Caregivers (Family and Friends)
Primary: Hospital Anxiety and Depression Scale Score — 16.6; 15.3; 15.6; 15.9 units on a scale (HADS summary score)
Phase 2 N=289 Magnesium Oxide in Treating Postmenopausal Women With Hot Flashes and a History of Breast Cancer
Breast Cancer · Cancer Survivor · Hot Flashes
Primary: The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. — 16.02; 15.35; 17.28; 14.28 units on a scale — p=0.13
Phase 3 N=351 Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule
Infections, Streptococcal
Primary: Number of Seroprotected Subjects Against Pneumococcal Serotypes — 149; 149; 150; 152 Subjects
Phase 2 N=94 Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Metastatic Renal Cell Carcinoma
Primary: Proportion of Patients Alive and Progression-free at 8 Weeks — 0.70; 0.52 proportion of participants
Phase 2 N=150 Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer
Rash
Primary: Overall Incidence of Rash — 84; 84; 82 percentage of participants — p=0.8769
Phase 3 N=158 Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide
Hyperparathyroidism, Secondary
Primary: Percentage of Participants With Serum Corrected Calcium < 7.5 mg/dL During the 4-week Treatment Period — 0.7 percentage of participants
Phase 4 N=24 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation
Coronary Artery Disease
Primary: Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF. — 84; 38; 94; 53 % inhibitn of platelet aggregation — p=0.001
Phase 3 N=694 S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
Breast Cancer
Primary: Time to Tumor Progression — 13.5; 15.0 months — p=0.007
Phase 3 N=257 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
Breast Cancer · Infertility · Menopausal Symptoms
Primary: Rate of Premature Ovarian Failure at 2 Years — 15; 5 Participants
Phase 4 N=85 Contribution of Pancreatic αcells Function to Blood Glucose Regulation in Chinese Type 2 Diabetics- the Effect of Sitagliptin on Glucagon Secretion, Insulin Secretion and Insulin Resistance in Chinese Type 2 Diabetics
Insulin Secretion · Insulin Resistance
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) — -1.08 percentage
Phase 4 N=78 An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
Adult Growth Hormone Deficiency
Primary: Percentage of Subjects Developing Binding Antibodies (BAbs) to Saizen® — 0 percentage of subjects
N/A N=26 Multi-Center Trial to Evaluate an Internal Joint Stabilizer - Elbow
Trauma · Chronic Elbow Dislocation
Primary: Broberg Morrey Functional Rating — 14; 8; 1; 1 Participants